International Journal of Hematology

, Volume 76, Issue 4, pp 310–318 | Cite as

Adeno-Associated Virus —Mediated Gene Transfer for Hemophilia B

  • Katherine A. High
Progress in hematology


Hemophilia is the bleeding diathesis caused by mutations in the gene encoding factor VIII (hemophilia A) or factor IX (hemophilia B). Currently, the disease is treated by intravenous infusion of the missing purified clotting factor. The goal of gene transfer for treating hemophilia is to achieve sustained expression of factor VIII or factor IX at levels high enough to improve the symptoms of the disease. Hemophilia has proven to be an attractive model for those interested in gene transfer, and multiple gene-transfer strategies are currently being investigated for the hemophilias. The most promising preclinical studies have been with adeno-associated viral vectors (AAV); introduction of AAV vectors expressing factor IX into skeletal muscle or liver in hemophilic dogs has resulted in the long-term expression of factor IX at levels that are adequate to improve disease symptoms. Efforts to translate these findings into the clinical arena have proceeded slowly because of the lack of prior clinical experience with parenteral administration of AAV. In a staged approach, AAV-factor IX (AAV-F.IX) was first administered at doses of up to 1.8 X 1012 vector genomes/kg (vg/kg) into the skeletal muscles of men with hemophilia B. This trial established the safety of parenteral administration and also showed that general characteristics of AAV transduction were similar in mice, dogs, and humans. In an ongoing trial, AAV-F.IX is being administered into the hepatic circulation of men with severe hemophilia B. The goal of these studies is to identify a safe dose that reliably yields circulating levels of factor IX >2% of normal levels in all subjects. This goal has already been achieved in the hemophilia B dog model; the ongoing study will determine whether a similar result can be achieved in humans with hemophilia B.Int J Hematol. 2002; 76: 310-318.

Key words

Hemophilia B AAV Gene therapy Liver Muscle 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Kazazian HH, Tuddenham EGD Antonarakis SE. Hemophilia: A: deficiency of coagulation factor VIII. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic and Molecular Basis of Inherited Disease, Vol. 3. 8th ed. New York, NY: McGraw-Hill; 2001: 4367-4392.Google Scholar
  2. 2.
    Pollak ES, High KA. Hemophilia B: factor IX deficiency. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds.The Metabolic and Molecular Basis of Inherited Disease, Vol. 3. 8th ed. New York, NY: McGraw-Hill; 2001: 4393–4413.Google Scholar
  3. 3.
    HAMSTeRS: The Haemophilia A Mutation, Structure, Test and Resource Site. 2000. London, UK: MRC Clinical Sciences Centre. Available at: Scholar
  4. 4.
    Haemophilia B Mutation Database, Version 11. A database of point mutations and short additions and deletions in the factor IX gene. 2002. Available at: Bdatabase.html.Google Scholar
  5. 5.
    Choo KH, Gould KG, Rees DJG, Brownlee GG. Molecular-cloning of the gene for human anti-hemophilic factor-IX.Nature. 1982; 299: 178–180.CrossRefPubMedGoogle Scholar
  6. 6.
    Gitschier J, Wood WI, Goralka TM, et al. Characterization of the human factor VIII gene.Nature. 1984; 312: 326–330.CrossRefPubMedGoogle Scholar
  7. 7.
    Brettler DB, Alter HJ, Dienstag JL, Forsberg AD, Levine PH. Prevalence of hepatitis C virus antibody in a cohort of hemophilia patients.Blood. 1990; 76: 254–256.PubMedGoogle Scholar
  8. 8.
    Gerety RJ, Eyster ME, Tabor E, et al. Hepatitis B virus, hepatitis A virus and persistently elevated aminotransferases in hemophiliacs.J Med Virol. 1980; 6: 111–118.CrossRefPubMedGoogle Scholar
  9. 9.
    Makris M, Preston FE,Triger DR, et al. Hepatitis C antibody and chronic liver disease in haemophilia.Lancet. 1990; 335: 1117–1119.CrossRefPubMedGoogle Scholar
  10. 10.
    Ragni MV, Winkelstein A, Kingsley L, Spero JA, Lewis JH. 1986 update of HIV seroprevalence, seroconversion, AIDS incidence and immunologic correlates of HIV infection in patients with hemophilia A and B.Blood. 1987; 70: 786–790.PubMedGoogle Scholar
  11. 11.
    Rumi GM, Colombo M, Gringeri A, Mannucci PM. High prevalence of antibody to hepatitis C virus in multitransfused hemophiliacs with normal transaminase levels.Ann Intern Med. 1990; 112: 379–380.CrossRefPubMedGoogle Scholar
  12. 12.
    Blanchette VS, Vorstman E, Shore A, et al. Hepatitis C infection in children with hemophilia A and B.Blood. 1991; 78: 285–289.PubMedGoogle Scholar
  13. 13.
    Soucie JM, Nuss R, Evatt B et al. Mortality among males with hemophilia: relations with source of medical care. The Hemophilia Surveillance System Project Investigators.Blood. 2000; 15: 437–442.Google Scholar
  14. 14.
    Lofqvist T, Nilsson IM, Berntorp E, Pettersson H. Haemophilia prophylaxis in young patientsa long-term follow-up.J Intern Med. 1997; 241: 395–400.CrossRefPubMedGoogle Scholar
  15. 15.
    Kyrle PA, Minar E, Hirschl M, et al. High plasma levels of factor VIII and the risk of recurrent venous thromboembolism.N Engl J Med. 2000; 34: 457–462.CrossRefGoogle Scholar
  16. 16.
    van Hylckama Vlieg A, van der Linden IK, Bertina RM, Rosendaal FR. High levels of factor IX increase the risk of venous thrombosis.Blood. 2000; 95: 3678–3682.Google Scholar
  17. 17.
    Bi L, Lawler AM, Antonarakis SE, High KA, Gearhart JD, Kazazian HH. Targeted disruption of the mouse factor VIII gene: a model for hemophilia A.Nat Genet. 1995; 10: 119–121.CrossRefPubMedGoogle Scholar
  18. 18.
    Lin HF, Maeda N, Smithies O, Straight DL, Stafford DW. A coagulation factor IX-deficient mouse model for human hemophilia B.Blood. 1997; 90: 3962–3966.PubMedGoogle Scholar
  19. 19.
    Wang L, Zoppe M, Hackeng TM, Griffin JH, Lee KF, Verma IM. A factor IX-deficient mouse model for hemophilia B gene therapy.Proc Natl Acad Sci U S A. 1997; 94: 11563–11566.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Cameron C, Notley C, Hoyle S, et al. The canine factor VIII cDNA and 5 flanking sequence.Thromb Haemost. 1998; 79: 317–322.CrossRefPubMedGoogle Scholar
  21. 21.
    Mauser AE, Whitney KM, Lothrop CD Jr. A deletion mutation causes hemophilia B in Lhasa Apso dogs.Blood. 1996; 88: 3451–3455.PubMedGoogle Scholar
  22. 22.
    Evans JP, Brinkhous KM, Brayer GD, Reisner HM, High KA. Canine hemophilia B resulting from a point mutation with unusual consequences.Proc Natl Acad Sci U S A. 1989; 86: 10095–10099.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Evans JP, Watzke HH, Ware JL, Stafford DW, High KA. Molecular cloning of a cDNA encoding canine factor IX.Blood. 1989; 74: 207–212.PubMedGoogle Scholar
  24. 24.
    Wu SM, Stafford DW, Ware JL. Deduced amino acid sequence of mouse blood-coagulation factor IX.Gene. 1990; 86: 275–278.CrossRefPubMedGoogle Scholar
  25. 25.
    Kay MA, Rothenberg S, Landen CN, et al. In vivo gene therapy of hemophilia B: sustained partial correction in factor IX-deficient dogs.Science. 1993; 262: 117–119.CrossRefPubMedGoogle Scholar
  26. 26.
    Kay MA, Landen CN, Rothenberg SR, et al. In vivo hepatic gene therapy: complete albeit transient correction of factor IX deficiency in hemophilia B dogs.Proc Natl Acad Sci U S A. 1994; 91: 2353–2357.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Miller DD, Alexander IE, Halbert CL, Russell DW. Persistent expression of human clotting factor IX from mouse liver after intravenous injection of adeno-associated virus vectors.Proc Natl Acad Sci U S A. 1997; 94: 1426–1431.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Xiao X, Li J, Samulski RJ. Efficient long-term gene transfer into muscle tissue of immunocompetent mice by adeno-associated virus vector.J Virol. 1996; 70: 8098–8108.PubMedPubMedCentralGoogle Scholar
  29. 29.
    Kessler PD, Podsakoff GM, Chen X, et al. Gene delivery to skeletal muscle results in sustained expression and systemic delivery of a therapeutic protein.Proc Natl Acad Sci U S A. 1996; 93: 14082–14087.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    aplitt MG, Leone P, Samulski RJ, et al. Long-term gene expression and phenotypic correction using adeno-associated virus vectors in the mammalian brain.Nat Genet. 1994; 8: 148–154.CrossRefGoogle Scholar
  31. 31.
    Summerford C, Samulski RJ. Membrane-associated heparan sulphate proteoglycan is a receptor for adeno-associated virus type 2 virions.J Virol. 1998; 72: 1438–1445.PubMedPubMedCentralGoogle Scholar
  32. 32.
    Qing K, Mah C, Hansen J, Zhou S, Dwarki V, Srivastava A. Human fibroblast growth factor receptor 1 is a co-receptor for infection by adeno-associated virus 2 [see comments.].Nat Med. 1999; 5: 71–77.CrossRefPubMedGoogle Scholar
  33. 33.
    Wagner JA, Reynolds T, Moran ML, et al. Efficient and persistent gene transfer of AAV-CFTR in maxillary sinus.Lancet. 1998; 351: 1702–1703.CrossRefPubMedGoogle Scholar
  34. 34.
    Wagner JA, Moran ML, Messner AH, et al. A phase I/II study of tgAAV-CF for the treatment of chronic sinusitis in patients with cystic fibrosis.Hum Gene Ther. 1998; 9: 889–909.CrossRefPubMedGoogle Scholar
  35. 35.
    Aitken ML, Moss RB, Waltz DA, et al. A phase I study of aerosolized administration of tgAAVCF to cystic fibrosis subjects with mild lung disease.Hum Gen Ther. 2001; 12: 1907–1916.CrossRefGoogle Scholar
  36. 36.
    Ferrari FK, Xiao X, McCarty D, Samulski RJ. New developments in the generation of Ad-free, high-titer rAAV gene therapy vectors.Nat Med. 1997; 3: 1295–1297.CrossRefPubMedGoogle Scholar
  37. 37.
    Summerford C, Samulski RJ. Viral receptors and vector purification: new approaches for generating clinical-grade reagents.Nat Med. 1999; 5: 587–588.CrossRefPubMedGoogle Scholar
  38. 38.
    Xiao W, Chirmule N, Berta SC, McCullough B, Gao G, Wilson JM. Gene therapy vectors based on adeno-associated virus type 1.J Virol. 1999; 73: 3994–4003.PubMedPubMedCentralGoogle Scholar
  39. 39.
    Gao GP, Alvira M, Wang L, Calcedo R, Johnston J, Wilson JM. Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy.Proc Natl Acad Sci U S A. 2002; 99: 11854–11859.CrossRefPubMedPubMedCentralGoogle Scholar
  40. 40.
    Herzog R, Hagstrom N, Kung S, et al. Stable gene transfer and expression of human FIX following intramuscular injection of recombinant AAV.Proc Natl Acad Sci U S A. 1997; 94: 5804–5809.CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Matsushita T. Adeno-associated virus vector can be efficiently produced without helper virus.Gene Ther. 1998; 5: 938–945.CrossRefPubMedGoogle Scholar
  42. 42.
    Cheung WF, van den Born J, Kuhn K, Kjellen L, Hudson BG, Stafford DW. Identification of the endothelial cell binding site for factor IX.Proc Natl Acad Sci U S A. 1996; 93: 11068–11073.CrossRefPubMedPubMedCentralGoogle Scholar
  43. 43.
    Pruchnic R, Cao B, Peterson ZQ, et al. The use of adeno-associated virus to circumvent the maturation-dependent viral transduction of muscle fibers.Hum Gene Ther. 2000; 11: 521–536.CrossRefPubMedGoogle Scholar
  44. 44.
    Herzog R, Yang E, Couto L, et al. Long-term correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-associated viral vector.Nat Med. 1999; 5: 56–63.CrossRefPubMedGoogle Scholar
  45. 45.
    Hoyer LW. Why do so many haemophilia A patients develop an inhibitor?Br J Haematol. 1995; 90: 498–501.CrossRefPubMedGoogle Scholar
  46. 46.
    Arruda VR, Fields PA, Milner R, et al. Lack of germline transmission of vector sequences following systemic administration of recombinant AAV-2 vector in males.Mol Ther. 2001; 4: 586–592.CrossRefPubMedGoogle Scholar
  47. 47.
    Arruda VR, Hagstrom JN, Deitch J, et al. Posttranslational modifications of recombinant myotube-synthesized human factor IX.Blood. 2001; 97: 130–138.CrossRefPubMedGoogle Scholar
  48. 48.
    Nathwani AC, Davidoff A, Hanawa H, Zhou J, Vanin EF, Nienhuis AW. Factors influencing in vivo transduction by recombinant adeno-associated viral vectors expressing the human factor IX cDNA.Blood. 2001; 97: 1258–1265.CrossRefPubMedGoogle Scholar
  49. 49.
    Ge Y, Powell S, Van Roey M, McArthur JG. Factors influencing the development of an anti-factor IX (FIX) immune response following administration of adeno-associated virus-FIX.Blood. 2001; 97: 3733–3737.CrossRefPubMedGoogle Scholar
  50. 50.
    Mount JD, Herzog RW, Tillson DM, et al. Sustained phenotypic correction of hemophilia B dogs with a factor IX null mutation by liver-directed gene therapy.Blood. 2002; 99: 2670–2676.CrossRefPubMedGoogle Scholar
  51. 51.
    Kay MA, Manno CS, Ragni MV, et al. Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an A AV vector.Nat Genet. 2000; 24: 257–261.CrossRefPubMedGoogle Scholar
  52. 52.
    Manno CS, Glader B, Ragni MV, et al. A phase I trial of AAV- mediated muscle directed gene transfer for hemophilia B [abstract].Thromb Haemost. 2001. Abstract OC2492.Google Scholar
  53. 53.
    Herzog RW, Fields PA, Arruda VR, et al. Influence of vector dose on factor IX-specific T and B cell responses in muscle-directed gene therapy.Hum Gene Ther. 2002; 13: 1281–1291.CrossRefPubMedGoogle Scholar
  54. 54.
    Greelish JP, Su LT, Lankford EB, et al. Stable restoration of the sarcoglycan complex in dystrophic muscle perfused with histamine and a recombinant adeno-associated viral vector.Nat Med. 1999; 5: 439–443.CrossRefPubMedGoogle Scholar
  55. 55.
    Arruda VR, Stedman H, Nichols TC, et al. Sustained correction of hemophilia B phenotype following intravascular delivery of AAV vector to skeletal muscle.Mol Ther. 2002; 5: S157.Google Scholar
  56. 56.
    Fisher KJ, Gao G-P, Weitzman MD, DeMatteo R, Burda JF, Wilson JF. Transduction with recombinant adeno-associated virus for gene therapy is limited by leading-strand synthesis.J Virol. 1996; 70: 520–532.PubMedPubMedCentralGoogle Scholar
  57. 57.
    Nakai H, Herzog R, Hagstrom JN, et al. AAV-mediated gene transfer of human blood coagulation factor IX into mouse liver.Blood. 1998; 91: 4600–4607.PubMedGoogle Scholar
  58. 58.
    Snyder RO, Miao CH, Patijn GA, et al. Persistent and therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectors.Nat Genet. 1997; 16: 270–276.CrossRefPubMedGoogle Scholar
  59. 59.
    Nakai H, Ohashi K, Arruda V, et al. A proposed rAAV-liver directed clinical trial for hemophilia B.Blood. 2000; 96: 798a.Google Scholar
  60. 60.
    Snyder RO, Miao C, Meuse L, et al. Correction of hemophilia B in canine and murine models using recombinant adeno-associated viral vectors.Nat Med. 1999; 5: 64–70.CrossRefPubMedGoogle Scholar
  61. 61.
    Wang L, Nichols TC, Read MS, Bellinger DA,Verma IM. Sustained expression of therapeutic level of factor IX in hemophilia B dogs by AAV-mediated gene therapy in liver.Mol Ther. 2000; 1: 154–158.CrossRefPubMedGoogle Scholar
  62. 62.
    Herzog RW, Mount JD, Arruda VR, High KA, Lothrop CD Jr. Muscle-directed gene transfer and transient immune suppression result in sustained partial correction of canine hemophilia B caused by a null mutation.Mol Ther. 2001; 4: 192–199.CrossRefPubMedGoogle Scholar
  63. 63.
    Okuyama T, Huber RM, Bowling W, et al. Liver-directed gene therapy: a retroviral vector with a complete LTR and the ApoE enhancer-alpha(1)-antitrypsin promoter dramatically increases expression of human alpha(1)-antitrypsin in vivo.Hum Gene Ther. 1996; 7: 637–645.CrossRefPubMedGoogle Scholar
  64. 64.
    Pastore L, Morral N, Zhou H, et al. Use of a liver-specific promoter reduces immune response to the transgene in adenoviral vectors.Hum Gene Ther. 1999; 10: 1773–1781.CrossRefPubMedGoogle Scholar
  65. 65.
    Nathwani AC, Davidoff AM, Hanawa H, et al. Sustained high level expression of human factor IX (hFIX) after liver-targeted delivery of recombinant adeno-associated virus encoding the hFIX gene in rhesus macaques.Blood. 2002; 100: 1662–1669.CrossRefPubMedGoogle Scholar
  66. 66.
    Miao CH, Nakai H, Thompson AR, et al. Nonrandom transduction of recombinant adeno-associated virus vectors in mouse hepatocytes in vivo: cell cycling does not influence hepatocyte transduction.J Virol. 2000; 74: 3793–3803.CrossRefPubMedPubMedCentralGoogle Scholar
  67. 67.
    Department of Health and Human Services, National Institutes of Health Recombinant DNA Advisory Committee, minutes of meeting. December 8-10, 1999, Bethesda, MD. National Institutes of Health Web site. Available at: minutes/1299rac.pdf.Google Scholar
  68. 68.
    Zhang Y, Chirmule N, Gao G-P, et al. Acute cytokine response to systemic adenoviral vectors in mice is mediated by dendritic cells and macrophages.Mol Ther. 2001; 3: 697–707.CrossRefPubMedGoogle Scholar
  69. 69.
    Schnell MA, Zhang Y, Tazelaar J, et al. Activation of innate immunity in nonhuman primates following intraportal administration of adenoviral vectors.Mol Ther. 2001; 3: 708–722.CrossRefPubMedGoogle Scholar
  70. 70.
    Mannucci PM. Modern treatment of hemophilia: from the shadows towards the light.Thromb Haemost. 1993; 70: 17–23.PubMedCrossRefGoogle Scholar
  71. 71.
    Bedossa P, Poynard T, Group MCS. An algorithm for the grading of activity in chronic hepatitis C.Hepatology. 1996; 24: 289–293.CrossRefPubMedGoogle Scholar
  72. 72.
    French METAVIR Cooperative Study Group. Interobserver and intraobserver variation in liver biopsy interpretation in patients with chronic hepatitis C.Hepatology. 1994; 20: 15–20.CrossRefGoogle Scholar
  73. 73.
    Gene therapy and the germline.Nat Med. 1999; 5: 245.Google Scholar
  74. 74.
    Farber D. Gene therapy: safer and virus-free?Science. 2001; 294: 1638–1642.CrossRefGoogle Scholar
  75. 75.
    National Institutes of Health Recombinant DNA Advisory Committee minutes. June, 1998, Bethesda, MD. National Institutes of Health Web site. Available at: minutes/6-98min.htm.Google Scholar
  76. 76.
    Biological Response Modifiers Advisory Committee. Issues pertaining to inadvertent germline transmission of gene transfer vectors. May 9-10, 2002, Gaithersburg, MD. Food and Drug Administration Web site. Available at: briefing/3855B2_01.doc.Google Scholar
  77. 77.
    Frankel M, Chapman A. Human inheritable genetic modifications: assessing scientific, ethical, religious, and policy issues. 2000. American Association for the Advancement of Science Web site. Available at: Scholar
  78. 78.
    Department of Health and Human Services, National Institutes of Health Recombinant DNA Advisory Committee, minutes of meeting. December 6, 2001, Bethesda, MD. National Institutes of Health Web site. Available at: Scholar
  79. 79.
    Department of Health and Human Services, National Institutes of Health Recombinant DNA Advisory Committee, minutes of meeting. March 7-8, 2002, Bethesda, MD. National Institutes of Health Web site. Available at: Scholar
  80. 80.
    Donsante A, Vogler C, Muzyczka N, et al. Observed incidence of tumorigenesis in long-term rodent studies of rAAV vectors.Gene Ther. 2001; 8: 1343–1346.CrossRefPubMedGoogle Scholar
  81. 81.
    Biological Response Modifiers Advisory Committee meeting #31. October 24, 2001, Gaithersburg, MD. Food and Drug Administration Web site. Available at: 01/transcripts/3794t1.doc.Google Scholar
  82. 82.
    Biological Response Modifiers Advisory Committee, 28th meeting. November 16-17, 2000, Bethesda, MD. Food and Drug Administration Web site. Available at: cber00.htm.Google Scholar

Copyright information

© The Japanese Society of Hematology 2002

Authors and Affiliations

  1. 1.Division of HematologyThe Children ’s Hospital of PhiladelphiaPhiladelphia, PennsylvaniaUSA

Personalised recommendations